Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation
暂无分享,去创建一个
Bikram Chakraborty | Bonaventura Clotet | E. Domingo | B. Clotet | L. Menéndez-Arias | M. Quiñones-Mateu | J. Weber | M. Parera | Jan Weber | Miguel E. Quiñones-Mateu | Esteban Domingo | Antonio Mas | A. Mas | Mahlet Tadele | Mariona Parera | Héctor R. Rangel | Luis Menéndez-Arias | Miguel A. Martínez | H. Rangel | Bikram Chakraborty | M. Martínez | M. Tadele
[1] R. Shafer,et al. A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. , 2001, HIV sequence compendium.
[2] Bluma G. Brenner,et al. Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection , 2002, Journal of Virology.
[3] N. Graham,et al. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy. , 1999, Journal of human virology.
[4] J. Fantini,et al. Stable rearrangements of the β3–β4 hairpin loop of HIV‐1 reverse transcriptase in plasma viruses from patients receiving combination therapy , 1998, AIDS.
[5] J. Fantini,et al. Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations. , 2000, Virology.
[6] M. Ait-Khaled,et al. A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group. , 1999 .
[7] M. Hillebrand,et al. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. , 1999, AIDS.
[8] D. Katzenstein,et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. , 1998, The Journal of clinical investigation.
[9] D. Richman,et al. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy , 2000, AIDS.
[10] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.
[11] M. Moroni,et al. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure. , 2000, Journal of acquired immune deficiency syndromes.
[12] L. Reed,et al. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .
[13] B. Berkhout. HIV-1 Evolution under Pressure of Protease Inhibitors: Climbing the Stairs of Viral Fitness , 1999, Journal of Biomedical Science.
[14] J. Lisziewicz,et al. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. , 1997, The Journal of infectious diseases.
[15] J. Lisziewicz,et al. Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase. , 1999, Journal of molecular biology.
[16] J. Cherrington,et al. Adefovir and Tenofovir Susceptibilities of HIV‐1 After 24 to 48 Weeks of Adefovir Dipivoxil Therapy: Genotypic and Phenotypic Analyses of Study GS‐96‐408 , 2001, Journal of acquired immune deficiency syndromes.
[17] F. Mammano,et al. HIV drug resistance and viral fitness. , 2000, Advances in pharmacology.
[18] W. Sugiura,et al. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors. , 1999, Journal of human virology.
[19] P. Sharp,et al. Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization. , 1994, AIDS research and human retroviruses.
[20] R. Colonno,et al. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[21] E. Arts,et al. HIV-1 Fitness : Implications for Drug Resistance , Disease Progression , and Global Epidemic Evolution , 2002 .
[22] Brian T. Foley,et al. HIV Sequence Compendium 2018 , 2010 .
[23] Miguel Ángel Martínez,et al. Role of a dipeptide insertion between codons 69 and 70 of HIV‐1 reverse transcriptase in the mechanism of AZT resistance , 2000, The EMBO journal.
[24] D. Venzon,et al. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. , 1998, The Journal of infectious diseases.
[25] C. Boucher,et al. Implications of antiretroviral resistance on viral fitness , 2001, Current opinion in infectious diseases.
[26] E. De Clercq,et al. Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues , 2000, Antimicrobial Agents and Chemotherapy.
[27] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[28] E. Domingo,et al. Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy. , 2000, Virus research.
[29] E. Arts,et al. A Dual Infection/Competition Assay Shows a Correlation between Ex Vivo Human Immunodeficiency Virus Type 1 Fitness and Disease Progression , 2000, Journal of Virology.
[30] A. Omrani,et al. Multi-drug resistant HIV-1. , 2000, The Journal of infection.
[31] R. D. de Boer,et al. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs. , 2001, AIDS research and human retroviruses.
[32] B Clotet,et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. , 1998, JAMA.
[33] H. Mitsuya,et al. Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay , 1999, Journal of Virology.
[34] E. Rosenberg,et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. , 1999, JAMA.
[35] V. Calvez,et al. Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors , 2001, Antimicrobial Agents and Chemotherapy.
[36] V. Soriano,et al. Different Outcome in the First Two Patients with an HIV-1 Multinucleoside Drug-Resistant T69SSS Insertion in Spain , 1998, Antiviral therapy.
[37] T. Merigan,et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy , 1996, Journal of virology.
[38] D. Stuart,et al. A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance , 1999, Antimicrobial Agents and Chemotherapy.
[39] E. G. Shpaer,et al. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. , 1993, Science.
[40] Gilcher Ro. Human retroviruses and AIDS. , 1988 .
[41] M. Ait-Khaled,et al. A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group. , 1999, Journal of acquired immune deficiency syndromes.
[42] B. Larder,et al. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates , 1994, Antimicrobial Agents and Chemotherapy.